Celularity's PDA-002 Shows Promise in Phase 2 Trial for Diabetic Foot Ulcers with Peripheral Artery Disease
核心洞察
Celularity's Phase 2 trial of PDA-002, a placenta-derived cell therapy, demonstrated 38.5% complete wound closure rates in diabetic foot ulcers complicated by peripheral artery disease versus 22.6% with placebo.
The study enrolled 159 patients across 35 U.S. clinical sites, with PDA-002 showing faster healing, reduced complications, and favorable safety profile through two years of follow-up.
Currently no FDA-approved therapies exist specifically for diabetic foot ulcers with peripheral artery disease, representing a significant unmet medical need affecting nearly one million Americans annually.
Celularity Inc. (搜索) has announced positive Phase 2 results for PDA-002, a first-in-class regenerative therapy targeting diabetic foot ulcers complicated by peripheral artery disease (PAD). The multicenter, randomized, double-blind, placebo-controlled trial, published in the International Wound Journal, represents a significant advancement in addressing one of wound care's most challenging conditions.
Addressing Critical Unmet Medical Need
Approximately two million individuals in the United States are affected each year by diabetic foot ulcers, with nearly half having coexisting peripheral artery disease. This combination represents one of the most difficult and costly challenges in wound care, with an estimated annual economic burden exceeding $9 billion in the United States for diabetic foot ulcers alone.
Currently, no FDA-approved therapies are specifically indicated for diabetic foot ulcers complicated by PAD. The presence of PAD significantly compromises lower-extremity perfusion, leading to chronic tissue ischemia, impaired angiogenesis, and delayed wound repair. These ulcers are characterized by persistent inflammation, altered immune response, and diminished responsiveness to standard wound care interventions.
Phase 2 Trial Design and Results
The published study included 159 adult patients with chronic diabetic foot ulcers across 35 clinical sites in the United States. Participants received two intramuscular doses of either PDA-002 at one of three dosage levels (3 × 10⁶, 10 × 10⁶, or 30 × 10⁶ cells) or placebo. The primary efficacy endpoint measured complete wound closure within three months with healing remaining intact for at least four additional weeks—a more rigorous durability measure than the standard FDA definition requiring only two weeks.
In patients with PAD, the highest rates of wound closure were observed with the lowest PDA-002 dose (3 × 10⁶ cells), where 38.5% of ulcers completely healed versus 22.6% in the placebo group. The data also showed faster and more sustained healing in treated patients, along with fewer cases of new gangrene and foot infections compared to placebo recipients.
Safety Profile and Tolerability
Across all groups, PDA-002 was well tolerated with no serious side effects linked to the treatment. This favorable safety profile remained consistent through two years of follow-up, supporting the therapy's potential for clinical application.
Regulatory and Commercial Implications
"The publication of our PDA-002 Phase 2 results in the International Wound Journal is a significant milestone for Celularity, and importantly, for patients battling diabetic foot ulcers complicated by peripheral artery disease," said Robert J. Hariri, M.D., Ph.D., Celularity's Chairman and CEO. "Our data show that our investigational therapy can drive meaningful wound closure rates, reduce serious complications, and do so with a favorable safety profile."
The findings position Celularity for a confirmatory Phase 3 trial aimed at delivering the first FDA-approved targeted therapy in regenerative wound care for diabetic foot ulcer patients with PAD.
Florida Implementation Opportunity
As a qualified stem cell therapy under Florida statute (§ 458.3245), effective July 1, 2025, PDA-002 may offer licensed Florida physicians an important new tool in treating diabetic foot ulcer patients. According to a January 2025 Florida Diabetes Advisory Council report, diabetes afflicts an estimated 2.1 million Floridians, with 25.4% of those ages 65 and older affected—approximately 1.25 million people.
"By unleashing promising stem cell therapies like PDA-002, Florida has given physicians a potentially important new tool for the treatment of diabetic foot ulcers, a serious condition that afflicts over a quarter of a million Floridians ages 65 and older," said Dr. Hariri.
Mechanism of Action
PDA-002 is a mesenchymal stromal-like cell therapy product derived from the postpartum placenta. These cells possess potent angiogenic, immunomodulatory, and tissue-repair properties, offering a novel approach to wound healing in patients for whom current therapies are inadequate. The study's findings highlight the regenerative and angiogenic potential of PDA-002 in promoting durable ulcer closure using only two doses with no retreatment required.